Login / Signup

Characterization of purinergic signaling in tumor-infiltrating lymphocytes from lower- and high-grade gliomas.

Juliete Nathali SchollAugusto Ferreira WeberCamila Kehl DiasVinícius Pierdoná LimaLucas Kich GrunDiego ZamboninEduardo AnzolinWanderson Willian Dos Santos DiasWillian Pegoraro KusFlorencia Barbé-TuanaAna Maria de Oliveira BattastiniPaulo Valdeci WormFabrício Figueiró
Published in: Purinergic signalling (2023)
Malignant gliomas are highly heterogeneous glia-derived tumors that present an aggressive and invasive nature, with a dismal prognosis. The multi-dimensional interactions between glioma cells and other tumor microenvironment (TME) non-tumoral components constitute a challenge to finding successful treatment strategies. Several molecules, such as extracellular purines, participate in signaling events and support the immunosuppressive TME of glioma patients. The purinergic signaling and the ectoenzymes network involved in the metabolism of these extracellular nucleotides are still unexplored in the glioma TME, especially in lower-grade gliomas (LGG). Also, differences between IDH-mutant (IDH-Mut) versus wild-type (IDH-WT) gliomas are still unknown in this context. For the first time, to our knowledge, this study characterizes the TME of LGG, high-grade gliomas (HGG) IDH-Mut, and HGG IDH-WT patients regarding purinergic ectoenzymes and P1 receptors, focusing on tumor-infiltrating lymphocytes. Here, we show that ectoenzymes from both canonical and non-canonical pathways are increased in the TME when compared to the peripheral blood. We hypothesize this enhancement supports extracellular adenosine generation, hence increasing TME immunosuppression.
Keyphrases
  • high grade
  • low grade
  • wild type
  • peripheral blood
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • healthcare
  • peritoneal dialysis